 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Trial completion date, Trial primary completion date: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - Apr 11, 2024
P3, N=105, Recruiting, Sponsor: AstraZeneca
Trial completion date: Apr 2024 --> Nov 2024 | Trial primary completion date: Apr 2024 --> Nov 2024
- ||||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
Enrollment closed: A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (clinicaltrials.gov) - Mar 21, 2024
P3, N=2518, Active, not recruiting, Sponsor: Bond Avillion 2 Development LP
Trial completion date: Apr 2024 --> Nov 2024 | Trial primary completion date: Apr 2024 --> Nov 2024 Recruiting --> Active, not recruiting
- |||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Enrollment open: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - Jan 11, 2024
P3, N=105, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- ||||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
Enrollment change, Trial completion date, Trial primary completion date: A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (clinicaltrials.gov) - Nov 27, 2023
P3, N=2500, Recruiting, Sponsor: Bond Avillion 2 Development LP
Active, not recruiting --> Recruiting N=1910 --> 2500 | Trial completion date: May 2024 --> Mar 2025 | Trial primary completion date: May 2024 --> Mar 2025
- ||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Trial completion date, Trial primary completion date: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - Nov 27, 2023
P3, N=105, Active, not recruiting, Sponsor: AstraZeneca
N=1910 --> 2500 | Trial completion date: May 2024 --> Mar 2025 | Trial primary completion date: May 2024 --> Mar 2025 Trial completion date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jan 2024 --> Apr 2024
- ||||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - Oct 5, 2023
P3, N=105, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jan 2024 --> Apr 2024 N=76 --> 105 | Trial completion date: Oct 2023 --> Jan 2024 | Trial primary completion date: Oct 2023 --> Jan 2024
- ||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Trial primary completion date: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - Feb 24, 2023
P3, N=76, Active, not recruiting, Sponsor: AstraZeneca
N=76 --> 105 | Trial completion date: Oct 2023 --> Jan 2024 | Trial primary completion date: Oct 2023 --> Jan 2024 Trial primary completion date: Dec 2022 --> Oct 2023
- |||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Enrollment closed, Trial completion date, Trial primary completion date: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - Feb 15, 2023
P3, N=76, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: Dec 2022 --> Oct 2023 Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Oct 2023 | Trial primary completion date: May 2023 --> Dec 2022
- |||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Enrollment open: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - Oct 26, 2022
P3, N=76, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Oct 2023 | Trial primary completion date: May 2023 --> Dec 2022 Not yet recruiting --> Recruiting
- |||||||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
New P3 trial: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - Sep 26, 2022
P3, N=76, Not yet recruiting, Sponsor: AstraZeneca
- |||||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
Enrollment open: A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (clinicaltrials.gov) - Sep 10, 2022
P3, N=1910, Recruiting, Sponsor: Bond Avillion 2 Development LP
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
New P3 trial: A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (clinicaltrials.gov) - Aug 18, 2022
P3, N=1910, Not yet recruiting, Sponsor: Bond Avillion 2 Development LP
- ||||||| budesonide/salbutamol (PT027) / AstraZeneca, Avillion
Trial completion: MANDALA: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (clinicaltrials.gov) - Mar 17, 2022
P3, N=3123, Completed, Sponsor: Bond Avillion 2 Development LP
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| budesonide/salbutamol (PT027) / AstraZeneca, Avillion
Enrollment closed, Trial completion date, Trial primary completion date: MANDALA: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (clinicaltrials.gov) - Sep 28, 2021
P3, N=3123, Active, not recruiting, Sponsor: Bond Avillion 2 Development LP
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Jan 2022 | Trial primary completion date: Jul 2021 --> Jan 2022
- ||||||| budesonide/salbutamol (PT027) / AstraZeneca, Avillion
Trial completion: DENALI: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (clinicaltrials.gov) - Sep 27, 2021
P3, N=1001, Completed, Sponsor: Bond Avillion 2 Development LP
Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Jan 2022 | Trial primary completion date: Jul 2021 --> Jan 2022 Active, not recruiting --> Completed
- || albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Clinical, Journal: Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials. (Pubmed Central) - Jun 23, 2021
P2
Active, not recruiting --> Completed The effects of albuterol delivered via AS MDI and Proventil on bronchodilation were equivalent, supporting the selection of AS MDI 180 µg to be taken into Phase III clinical trials, either alone or in combination with an inhaled corticosteroid.
- ||||| budesonide/salbutamol (PT027) / AstraZeneca, Avillion
Enrollment closed: DENALI: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (clinicaltrials.gov) - Apr 30, 2021
P3, N=1001, Active, not recruiting, Sponsor: Bond Avillion 2 Development LP
The effects of albuterol delivered via AS MDI and Proventil on bronchodilation were equivalent, supporting the selection of AS MDI 180 µg to be taken into Phase III clinical trials, either alone or in combination with an inhaled corticosteroid. Recruiting --> Active, not recruiting
- |||| budesonide/salbutamol (PT027) / AstraZeneca, Avillion
Trial completion date, Trial primary completion date: MANDALA: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (clinicaltrials.gov) - Aug 8, 2020
P3, N=3100, Recruiting, Sponsor: Bond Avillion 2 Development LP
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Sep 2020 --> Jul 2021
- ||||| budesonide/salbutamol (PT027) / AstraZeneca, Avillion
Enrollment change, Trial completion date, Trial primary completion date: DENALI: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (clinicaltrials.gov) - Aug 8, 2020
P3, N=1030, Recruiting, Sponsor: Bond Avillion 2 Development LP
Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Sep 2020 --> Jul 2021 N=600 --> 1030 | Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2020 --> May 2021
- ||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Trial completion: A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately. (clinicaltrials.gov) - May 20, 2019
P1, N=91, Completed, Sponsor: AstraZeneca
N=600 --> 1030 | Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2020 --> May 2021 Active, not recruiting --> Completed
- || Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Enrollment closed: A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately. (clinicaltrials.gov) - Apr 25, 2019
P1, N=76, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||| budesonide/salbutamol (PT027) / AstraZeneca, Avillion
Enrollment open: DENALI: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (clinicaltrials.gov) - Mar 28, 2019
P3, N=600, Recruiting, Sponsor: Bond Avillion 2 Development LP
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Enrollment open: A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately. (clinicaltrials.gov) - Feb 21, 2019
P1, N=90, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| budesonide/salbutamol (PT027) / AstraZeneca, Avillion
New P3 trial: DENALI: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (clinicaltrials.gov) - Feb 20, 2019
P3, N=600, Not yet recruiting, Sponsor: Bond Avillion 2 Development LP
- |||||| budesonide/salbutamol (PT027) / AstraZeneca, Avillion
Enrollment open: MANDALA: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (clinicaltrials.gov) - Jan 23, 2019
P3, N=3100, Recruiting, Sponsor: Bond Avillion 2 Development LP
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
New P1 trial: A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately. (clinicaltrials.gov) - Dec 11, 2018
P1, N=90, Not yet recruiting, Sponsor: AstraZeneca
- |||||||||| budesonide/salbutamol (PT027) / AstraZeneca, Avillion
New P3 trial: MANDALA: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (clinicaltrials.gov) - Dec 7, 2018
P3, N=3100, Not yet recruiting, Sponsor: Bond Avillion 2 Development LP
- |||| albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Trial completion: Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma (clinicaltrials.gov) - Apr 6, 2018
P2, N=86, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Enrollment closed: Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma (clinicaltrials.gov) - Mar 14, 2018
P2, N=86, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Enrollment open: Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma (clinicaltrials.gov) - Dec 14, 2017
P2, N=70, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
New P2 trial: Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma (clinicaltrials.gov) - Dec 6, 2017
P2, N=70, Not yet recruiting, Sponsor: Pearl Therapeutics, Inc.